NICE 'cash-back' deal unlikely to be the norm

The NHS 'cash-back' scheme for bortexomib (Velcade) approved by NICE last week is unlikely to become the norm, say experts.

For the first time, NICE approved NHS use of a drug under a response-rebate scheme. This means that if a patient shows no response to the drug, the manufacturer has to refund its cost to the NHS.

NICE said the scheme was only considered after being suggested by manufacturer Janssen-Cilag.

If response-rebate is to be considered in the future, it would have to be suggested by manufacturers and be approved in principle by the DoH.

A NICE spokesman said: 'There are a number of factors that might need to be considered, such as whether it would be clinically appropriate for continuation of treatment to be determined on the basis of an appropriate response measure and how well the response measure predicts actual health outcomes.'

The scheme applies to patients with multiple myeloma who have had one prior therapy and for whom blood marrow transplantation has failed or is unsuitable.

At first relapse, eligible patients can be given bortexomib. If they show a full or partial response they will be allowed to continue with the treatment, funded by the NHS.

If the patient fails to respond, treatment will stop and Janssen-Cilag will refund the NHS the cost of the drug, says NICE.

Richard Ley, spokesman for the Association of the British Pharmaceutical Industry, said the scheme was likely to be 'the exception, not the norm'.

'They can't all do it,' he said. 'The reason is that Velcade is in a peculiar position.'

Within a few weeks of use, doctors can identify markers to see if the drug is being effective.

rachel.liddle@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS England to redesign GP appraisal in light of COVID-19 pandemic

NHS England to redesign GP appraisal in light of COVID-19 pandemic

GP appraisals are being redesigned to have a greater focus on wellbeing and reduced...

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Hundreds of millions of pounds could be lost to primary care if primary care networks...

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

GP practices have been told to 'gear up for a major expansion of the winter flu programme'...

NHS England unveils GP contract plans for second phase of COVID-19 response

NHS England unveils GP contract plans for second phase of COVID-19 response

GPs have been told to re-start health checks and other suspended services as NHS...

More than 80% of patients report 'good' overall experience of general practice

More than 80% of patients report 'good' overall experience of general practice

Public satisfaction with GP services remains high, with 82% of patients reporting...

GPs condemn 'deafening silence' from chancellor on COVID support funding

GPs condemn 'deafening silence' from chancellor on COVID support funding

GP leaders have condemned a 'deafening silence' on COVID-19 relief funding for general...